<div id="readability-page-1"><div><h2>Savara stock in focus after recent performance and fundamentals</h2> <p>Savara (SVRA) has come into focus after recent share price weakness, including a 3.9% decline in the latest session and negative returns over the past week and month, despite strong multi year total returns.</p> <p>The company has a market value of about US$1.3b, no reported revenue and a net loss of US$118.8 million. This puts the spotlight on its clinical stage pipeline and cash needs rather than current profitability.</p> <p>See our latest analysis for Savara.</p> <p>At a share price of US$4.94, Savara has seen recent pressure, including a 1 day share price return decline of 3.9% and a 90 day share price return decline of 17.9%. However, the 1 year total shareholder return sits at 51.1%, indicating longer term holders have seen gains despite fading short term momentum.</p> <p>If you are weighing up opportunities in healthcare and biotech, it can help to compare Savara with other names using a focused screener for growth ideas, such as 34 healthcare AI stocks.</p> <p>With the share price under pressure in recent months, but a 51.1% 1 year total return and a roughly US$1.3b valuation for a zero revenue, loss making business, is this weakness a chance to buy in, or is the market already pricing in future growth?</p> <h2>Preferred price to book multiple of 6.2x: Is it justified?</h2> <p>Savara trades on a P/B ratio of 6.2x, which looks attractive relative to its specific peer set but expensive compared with the broader US biotech group.</p> <p>The P/B ratio compares the company’s market value with its book value, essentially what its net assets are worth on the balance sheet. For a clinical stage biotech with no revenue and a net loss of $118.8 million, investors are often paying for future pipeline potential and expected cash flows rather than current earnings.</p> <p>According to the data, Savara is described as good value against its closest peers, with a 6.2x P/B ratio versus a 18.7x peer average. That suggests the market is assigning a lower balance sheet multiple than similar companies focused on rare respiratory diseases, which some investors may interpret as a more conservative stance on its prospects.</p> <p>However, when the comparison shifts to the wider US biotechs industry, the picture reverses. Savara’s 6.2x P/B is described as expensive relative to the sector average of 2.5x, implying investors are paying a higher multiple of book value than for the typical biotech name despite the company having no reported revenue and ongoing losses.</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <p><strong>Result: Price to book ratio of 6.2x (ABOUT RIGHT)</strong></p> <p>However, this hinges on successful Phase 3 progress for molgramostim and ongoing access to funding, as the current US$118.8 million net loss underscores execution risk.</p> <p>Find out about the key risks to this Savara narrative.</p> <h2>Next Steps</h2> <p>Balancing that mix of risks and potential rewards, does the current setup match your expectations or feel out of line with them? Take a closer look at both sides of the story through 1 key reward and 2 important warning signs</p> <h2>Looking for more investment ideas?</h2> <p>If Savara has your attention, do not stop here. Broader context from other stocks can sharpen your thinking and help you spot better risk reward setups.</p> <ul> <li>Target potential value opportunities by checking companies highlighted in the 54 high quality undervalued stocks.</li> <li>Focus on balance sheet strength by reviewing the solid balance sheet and fundamentals stocks screener (42 results).</li> <li>Hunt for less crowded opportunities by scanning the screener containing 23 high quality undiscovered gems.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

SVRA

SBIO

LABU

<p>Savara (SVRA) has faced recent share price weakness, declining 3.9% in the latest session and 17.9% over the past 90 days, despite a 51.1% total return over the past year. The company, valued at approximately $1.3 billion, reports no revenue and a net loss of $118.8 million. Its price-to-book (P/B) ratio stands at 6.2x, which is attractive compared to peers but high relative to the broader biotech sector average of 2.5x. Investors are weighing the potential for future growth against ongoing losses and execution risks.</p>

Simplywall

Savara

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Assessing Savara (SVRA) Valuation After Recent Share Price Weakness And Ongoing Losses